BPC-157 Protocol

Evidence Level: Investigational / Theoretical

Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.

Human evidence: No large controlled human trials; scattered small studies and extensive anecdotal use exist but do not constitute clinical-grade evidence.

Animal evidence: Substantial rodent-model literature on tendon, ligament, muscle and gut healing.

Introduction & Mechanism of Action

Preclinical investigation of tissue response, vascular signaling and repair pathways.

Synthetic fragment derived from a gastric-protective protein; studied for promoting angiogenesis (via VEGF/FAK-paxillin pathway signaling in animal models) and modulating growth-factor expression in tendon, ligament and gut tissue.

Receptors/targets: No single confirmed receptor — proposed to act via growth-factor pathway modulation (VEGFR, FAK)

Areas of Research Interest

• Tissue-repair models
• Tendon and ligament models
• Gastrointestinal research

Benefits Reported in Research

• Tissue-repair research
• Tendon and ligament studies
• Gastrointestinal research

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 200–600 mcg

Reported frequency: 1–2× daily, subcutaneous

Reported cycle duration: 8–12 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on BPC-157 reports administration at 200–600 mcg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Injection-site irritation (most commonly reported)
• Fatigue or dizziness (anecdotal, not well quantified)

Contraindications

• Pregnancy
• Active malignancy (theoretical concern given angiogenic mechanism)

Drug interactions

• Not characterized — no controlled human drug-interaction studies exist

Safety

• No human safety database of meaningful size
• FDA has flagged immunogenicity and impurity-characterization concerns for compounded supply

Animal findings are not proven clinical benefits. FDA identifies limited safety information, immunogenicity and impurity-characterization concerns.

Expected Results & Comparison

BPC-157 and TB-500 are the two most-studied repair peptides and are frequently used together (see BPC-157 + TB-500) because their proposed mechanisms are complementary — BPC-157 is more associated with gut and tendon/ligament research, TB-500 with cell migration and angiogenesis broadly.

References

Continue